Clinical trial NCT02686268: Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS
Official title: Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
Keywords: Amyotrophic Lateral Sclerosis
ALS
C9ORF72 gene mutation
Chromosome 9 open reading frame 72 protein
Natural history
Biomarkers
Amyotrophic Lateral Sclerosis, Familial
Amyotrophic Lateral Sclerosis, Sporadic
Frontotemporal Dementia-Amyotrophic Lateral Sclerosis
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
Collaborators: name: Cedars-Sinai Medical Center
name: UMC Utrecht
name: Johns Hopkins University
name: Massachusetts General Hospital
name: University of Massachusetts, Amherst
name: Biogen
name: ALS Association
name: Columbia University
First posted: 2016-02-19
Enrollment: 128
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Known positive C9ORF72 ALS status upon enrollment

Brief summary: This research study is being performed to better understand a specific form of Amyotrophic Lateral Sclerosis (ALS) caused by a mutation (or abnormality) of the C9ORF72 gene. This mutation is the most common genetic cause of ALS, and is present in 40% of ALS patients with a family history of ALS and 5-10% of ALS patients without a family history of ALS.

Detailed description: Individuals diagnosed with ALS, who are confirmed to carry the Chromosome 9 Open Reading Frame 72 (C9ORF72) gene mutation by CLIA-certified lab results, are eligible for enrollment. Researchers want to understand the natural history of C9ORF72 related ALS in terms of measures of rate of progression as well as understanding how the size of the hexanucleotide repeat expansion influences disease parameters. The investigators hope that the intense study of patients with the C9ORF72 mutation will ultimately help us develop treatments for this common form of ALS.

Objectives:

* Enroll a total of 120 C9ORF72 ALS participants with known mutation at the time of enrollment.
* Determine the C9ORF72 hexanucleotide repeat expansion size in all subjects
* Define ALS disease course
* Determine to what degree the disease course correlates with expansion size
* Collect biomarker samples (blood, DNA and CSF)

Eligibility:

- Adults over age 18 with known C9ORF72 ALS status

Design:

Participants will have up to 9 in-person visits (this includes two Optional visits for lumbar puncture procedures) and 5 telephone interviews over 3 years. Each in-person visit may be tied to a regular clinic visit if subject is local (except for the optional lumbar puncture visits) or if the subject is from out of town one initial visit can be set up with all other visits performed via a telephone call and medical records review.

At each in town visit, subjects will undergo a blood draw (optional lumbar puncture) and two questionnaires (ALS Functional Rating Scale - revised ALSFRS-R) which measures motor function and the ALS-Cognitive Behavioral Screen (ALS-CBS) which will detect signs of Frontal Temporal Dementia and a breathing test to determine Slow Vital Capacity (SVC) measurements.

For out of town subjects - blood draws can be scheduled locally and sent to the study site for analysis. The ALSFRS-R can be performed over the phone along with other study related questions.

The C9ORF72 mutation is called a "dominant" mutation, which means that their children have a 50% chance of inheriting the gene. Most people who inherit the C9ORF72 mutation will develop either ALS or the related disease called fronto-temporal dementia. However, it may be possible for someone to test positive for the C9ORF72 gene mutation and never develop symptoms. Furthermore, in addition to C9ORF72, there are many other gene mutations that can cause ALS. This study will not test these other genes, and therefore a negative test result for the C9ORF72 mutation will not exclude the possibility that you have a heritable form of ALS.

In order to understand the natural history of C9ORF72 related ALS in terms of measures of rate of progression, the investigators need to understand how the size of the hexanucleotide repeat expansion influences disease parameters. A C9ORF72-focused clinical trial defining an accurate historical control population, will be critical since there may not be enough subjects for a placebo controlled trial. To be ready for upcoming therapeutic trials, the investigators need to start the detailed characterization of the C9ORF72 patients immediately.

Eligibility criteria: Inclusion:

1. Males or females of any race aged 18 or older
2. Known positive C9ORF72 ALS status via CLIA-certified lab results.
3. Capable of providing informed consent and following study procedures. In the event that an individual lacks the ability to provide informed consent, informed consent may be sought from the individual's legal, surrogate representative.
4. Geographically accessible to the site.

Exclusion:

1. Geographically inaccessible to the site
2. C9ORF72 ALS negative via CLIA-certified lab results

Primary outcomes:
measure: Collection of clinical data and biomarker samples
timeFrame: December 2017
Secondary outcomes:
measure: Correlation of repeat expansion size with clinical outcome measures and determination of C9ORF72 patients eligibility for clinical trials
timeFrame: December 2017
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Cedars Sinai Medical Center
state: California
city: Baltimore
country: United States
facility: Johns Hopkins
state: Maryland
city: Amherst
country: United States
facility: University of Massachusetts
state: Massachusetts
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Saint Louis
country: United States
facility: Washington University in St. Louis
state: Missouri
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
city: Virginia Beach
country: United States
facility: Sentara Health Care / Sentara Neurology Specialists
state: Virginia
city: Utrecht
country: Netherlands
facility: UMC Utrecht
Study officials:
affiliation: Washington University School of Medicine
name: Timothy M Miller, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Cammack AJ, Atassi N, Hyman T, van den Berg LH, Harms M, Baloh RH, Brown RH, van Es MA, Veldink JH, de Vries BS, Rothstein JD, Drain C, Jockel-Balsarotti J, Malcolm A, Boodram S, Salter A, Wightman N, Yu H, Sherman AV, Esparza TJ, McKenna-Yasek D, Owegi MA, Douthwright C; Alzheimer's Disease Neuroimaging Initiative; McCampbell A, Ferguson T, Cruchaga C, Cudkowicz M, Miller TM. Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology. 2019 Oct 22;93(17):e1605-e1617. doi: 10.1212/WNL.0000000000008359. Epub 2019 Oct 2.